Philip Astley-Sparke Sells 5,000 Shares of Uniqure NV (QURE) Stock

Share on StockTwits

Uniqure NV (NASDAQ:QURE) Director Philip Astley-Sparke sold 5,000 shares of the company’s stock in a transaction on Monday, December 3rd. The shares were sold at an average price of $30.39, for a total value of $151,950.00. Following the completion of the transaction, the director now directly owns 23,252 shares in the company, valued at approximately $706,628.28. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

QURE traded down $0.69 during mid-day trading on Thursday, hitting $28.93. 27,116 shares of the stock were exchanged, compared to its average volume of 596,626. Uniqure NV has a 1-year low of $14.68 and a 1-year high of $43.23. The company has a current ratio of 7.56, a quick ratio of 7.56 and a debt-to-equity ratio of 0.05. The firm has a market cap of $1.10 billion, a price-to-earnings ratio of -9.84 and a beta of 0.81.

Uniqure (NASDAQ:QURE) last posted its earnings results on Tuesday, November 6th. The biotechnology company reported ($0.59) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.62) by $0.03. Uniqure had a negative return on equity of 58.49% and a negative net margin of 725.04%. The firm had revenue of $3.15 million for the quarter, compared to analyst estimates of $3.37 million. On average, research analysts forecast that Uniqure NV will post -2.57 earnings per share for the current year.

Several equities analysts recently issued reports on the company. HC Wainwright increased their target price on Uniqure from $42.00 to $48.00 and gave the stock a “buy” rating in a research note on Monday, September 24th. Cantor Fitzgerald set a $58.00 target price on Uniqure and gave the stock a “buy” rating in a research note on Thursday, August 23rd. BidaskClub lowered Uniqure from a “strong-buy” rating to a “buy” rating in a research note on Friday, September 28th. Cowen reissued a “buy” rating on shares of Uniqure in a research note on Monday, August 13th. Finally, Janney Montgomery Scott reissued a “buy” rating on shares of Uniqure in a research note on Wednesday, August 8th. One analyst has rated the stock with a sell rating, one has given a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $55.67.

Hedge funds have recently bought and sold shares of the business. Gagnon Securities LLC acquired a new stake in Uniqure in the 2nd quarter valued at about $209,000. Trexquant Investment LP acquired a new stake in Uniqure in the 2nd quarter valued at about $272,000. Oppenheimer & Co. Inc. acquired a new stake in Uniqure in the 3rd quarter valued at about $279,000. BlueMountain Capital Management LLC acquired a new stake in Uniqure in the 2nd quarter valued at about $383,000. Finally, CIBC World Markets Inc. acquired a new stake in Uniqure in the 2nd quarter valued at about $392,000. 60.62% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION NOTICE: This news story was published by Fairfield Current and is the sole property of of Fairfield Current. If you are accessing this news story on another site, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The correct version of this news story can be read at https://www.fairfieldcurrent.com/news/2018/12/06/philip-astley-sparke-sells-5000-shares-of-uniqure-nv-qure-stock.html.

Uniqure Company Profile

uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. The company develops AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia; and AMT-126, a gene therapy for the treatment of congestive heart failure and AMT-130 to treat huntington's disease.

Read More: Institutional Investors

Insider Buying and Selling by Quarter for Uniqure (NASDAQ:QURE)

Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply